Psychiatr. praxi 2019; 20(2): 88-91 | DOI: 10.36290/psy.2019.020
Agomelatin – tolerance with great effect
- Klinika psychiatrie Fakultní nemocnice, Olomouc
Agomelatine is antidepresive substance, which development started in early 90s and was introduced into clinical practice in the first decade of new millenium. Agomelatine has extraordinary and clear farmacological profile that puts it into individual antidepresant group. Efficiency of agomelatine is simillar to the effect of SSRI antidepresives. Only minimal side effects connected to sexual dysfunctinon and weight gain are reported. Agomelatine has dual effect. It repairs disturb sleep rhytms due to stimulation of melatonergic receptos in nucleus suprachiasmatichus and andepressive effect is caused by anatagonist function on serotonergic receptors 5HT2C , that releases norepinephrin and dopamine into frontal cortex. It is necessary to check liver enzymes before administrating agomelatine and again few weeks and months into the therapy. Agomelatin is potent in treatment of depresive symptoms, anxiety and sleep disorders.
Keywords: agomelatine, sleep disorders, depression, anxiety, circadian rhytm, tolerance of treatment
Published: June 1, 2019 Show citation
References
- Serna M, Catalina, et al. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. European Psychiatry, 2010, 25.4: 206-213.
Go to original source... - Tardito D, et al. Synergistic mechanisms involved in the antidepressant effects of agomelatine. European Neuropsychopharmacology, 2012, 22: S482-S486. Go to original source...
Go to PubMed... - Carpentieri A., et al. New perspectives in melatonin uses. Pharmacological research, 2012, 65.4: 437-444. Go to original source...
- Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, 2013. 313-317.
- Stein DJ, et al. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. European Neuropsychopharmacology, 2017, 27.5: 526-537. Go to original source...
- Höschl C. Agomelatin, antidepresivum, jež obnovuje cirkadiánní rytmy. Remedia, 2012, 22: 186-193.
- De Berardis D, et al. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. International journal of molecular sciences, 2015, 16.1: 1111-1130. Go to original source...
- Levitan MN, Papelbaum M, NardiAE. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder. Neuropsychiatric disease and treatment, 2015, 11: 1149. Go to original source...
- Goethe JW, et al. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. Journal of clinical psychopharmacology, 2007, 27.5: 451-458. Go to original source...
- Montejo AL, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Journal of psychopharmacology, 2010, 24.1: 111-120. Go to original source...
- Stahl SM. Prescriber's Guide: Antidepressants: Stahl's Essential Psychopharmacology. Cambridge University Press, 2017. 5-8.
- Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus, 2018, 16.4: 420-429. Go to original source...
- Laux G, et al. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry, 2012, 45.07: 284-291. Go to original source...
- Demyttenaere K. Agomelatine: a narrative review. European Neuropsychopharmacology, 2011, 21: S703-S709. Go to original source... Go to PubMed...